Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Liquidity Services Inc
NASDAQ:LQDT
|
US |
|
CIE Automotive India Ltd
NSE:CIEINDIA
|
IN |
Abivax SA
Other Current Liabilities
Abivax SA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Other Current Liabilities
€1.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-6%
|
|
|
Valneva SE
PAR:VLA
|
Other Current Liabilities
€28.6m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
25%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Current Liabilities
€21.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
52%
|
CAGR 10-Years
14%
|
|
|
Inventiva SA
PAR:IVA
|
Other Current Liabilities
€12.7m
|
CAGR 3-Years
79%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Current Liabilities
$1.7m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
4%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other Current Liabilities
€26m
|
CAGR 3-Years
22%
|
CAGR 5-Years
20%
|
CAGR 10-Years
30%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Other Current Liabilities?
Other Current Liabilities
1.7m
EUR
Based on the financial report for Dec 31, 2025, Abivax SA's Other Current Liabilities amounts to 1.7m EUR.
What is Abivax SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-6%
Over the last year, the Other Current Liabilities growth was 0%. The average annual Other Current Liabilities growth rates for Abivax SA have been -23% over the past three years , -34% over the past five years , and -6% over the past ten years .
